Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma

Ajai Chari, MD, discusses treatment navigation in relapsed/refractory multiple myeloma in the era of CAR T-cell therapies and bispecific antibodies.

Tycel Phillips, MD, discusses considerations for navigating treatment options in relapsed/refractory mantle cell lymphoma.

Diana Cirstea, MD, discusses sequencing considerations in relapsed/refractory multiple myeloma in the era of T-cell–redirecting therapies.

Alexey Danilov, MD, PhD, and Tycel Phillips, MD, highlight key consensus viewpoints in lymphoma published from the 2025 Bridging the Gaps meeting.

Ajai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.

Ajai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.

Andrew Kuykendall, MD, explains considerations for JAK inhibitor sequencing and the use of transplant in myelofibrosis.

Alexey Danilov, MD, PhD, discusses second-line treatment selection for patients with chronic lymphocytic leukemia who have received venetoclax-based regimens.

Jesús Berdeja, MD, discusses the optimal timing of CAR T-cell therapy referral for patients with multiple myeloma.

Tara Graff, DO, details the role of CAR T-cell therapy in the relapsed/refractory diffuse large B-cell lymphoma treatment paradigm.

Amrita Krishnan, MD, discusses risk stratification in smoldering myeloma and factors that inform the classification of high-risk disease.

Jae Park, MD, discusses the importance and utility of MRD testing in the current acute lymphoblastic leukemia management field.

Rami Komrokji, MD, discusses strategies and barriers for utilizing current risk-stratification tools in myelodysplastic syndromes.

Daniel J. DeAngelo, MD, PhD, discusses debate points in acute lymphoblastic leukemia care that future research could address.

Hetty E. Carraway, MD, MBA, highlights the evolving molecular classification of MDS and novel agents in the therapeutic arsenal.

Hetty E. Carraway, MD, MBA, discusses shifting treatment paradigms in AML from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Ajai Chari, MD, expands on areas of uncertainty in multiple myeloma after his presentation at the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Ajai Chari, MD, highlighted key areas of debate in smoldering myeloma from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Alexey Danilov, MD, PhD, discussed how chemotherapy-free regimens have influenced treatment decision-making for patients with mantle cell lymphoma.

Alexey Danilov, MD, PhD, highlights the importance of re-evaluating sequencing strategies amid a growing arsenal of targeted therapies in DLBCL.

Alexey Danilov, MD, PhD, shares key developments and areas of debate from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Alexey Danilov, MD, PhD, discusses the significance of a manuscript that was published following the first Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Dr Danilov highlights advances and questions in the management of mantle cell lymphoma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma.

Catherine C. Coombs, MD, discusses the need to establish a standardized definition of high-risk CLL.

Catherine C. Coombs, MD, discusses the challenges in establishing a treatment consensus for relapsed CLL.

Daniel DeAngelo, MD, PhD, discusses the need for consensus guidelines in the management of ALL, particularly in defining optimal treatment strategies for older adult patients.

Mazyar Shadman, MD, MPH, discusses the need for a clinical consensus in selecting optimal treatment strategies in diffuse large B-cell lymphoma.

Rami Komrokji, MD, discusses the importance of establishing a clinical consensus to standardize the use of molecular testing in myelodysplastic syndromes.

Amrita Krishnan, MD, discusses the challenges in developing a clinical consensus on risk stratification in smoldering multiple myeloma and its role in guiding treatment decisions.